Design, synthesis, and antitumor evaluation of morpholine substituted bisnaphthalimides as DNA targeting agents

A series of mono-and bisnaphthalimides derivatives containing 3-nitro and 4-morpholine moieties were designed, synthesized, and evaluated for their in vitro anticancer activities against four cancer cell lines. Some compounds exhibited relatively good antiproliferative activity on the cell lines tested, in comparison with mitonafide and amonafide. It is noteworthy that bisnaphthalimide A6 was identified as the most potent com-pound in anti-proliferation against MGC-803 cells, with an IC50 lowered to 0.09 mu M, a far greater potency than that of mono-naphthalimide A7, mitonafide, and amonafide. A gel electrophoresis assay revealed that DNA and Topo I were the potential targets of compounds A6 and A7. The treatment of CNE-2 cells with compounds A6 and A7 resulted in an S phase cell cycle arrest, accompanied by the upregulation of the expression levels of the antioncogene p27 and the down-regulation of the expression levels of CDK2 and cyclin E. In addition, compounds A6 and A7-induced apoptosis was further confirmed by flow cytometry, ROS generation assay, and Hoechst 33,258 staining. In particular, in vivo antitumor assay results revealed that bisnaphthalimide A6 exhibited potent anticancer efficiency in an MGC-803 xenograft tumor model, in comparison with mitonafide, and had lower toxicity than mono-naphthalimide A7. In brief, the results suggested that bisnaphthalimide derivatives con-taining 3-nitro and 4-morpholine moieties might serve as DNA binding agents for the development of new antitumor agents.

Automated summary

A series of mono-and bisnaphthalimides derivatives containing 3-nitro and 4-morpholine moieties were synthesized and evaluated for their anticancer activities. Bisnaphthalimide A6 exhibited the highest anticancer activity against MGC-803 cells, with a much greater potency than that of mono-naphthalimide A7, mitonafide, and amonafide. The compounds could bind to DNA and Topo I, leading to cell cycle arrest and apoptosis. In vivo studies confirmed the potent anticancer efficiency of bisnaphthalimide A6 in an MGC-803 xenograft tumor model.